<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457547</url>
  </required_header>
  <id_info>
    <org_study_id>217744/094</org_study_id>
    <nct_id>NCT01457547</nct_id>
  </id_info>
  <brief_title>Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course</brief_title>
  <official_title>Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and
      HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations</measure>
    <time_frame>Prior to the third primary vaccination dose ( Months 8-9)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations</measure>
    <time_frame>One month after the second and third primary vaccination dose (Month 3 and Months 9-10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to the components of the study vaccine in terms of number of seroprotected subjects defined by antibody concentration</measure>
    <time_frame>Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to the components of the study vaccine in terms of number of seropositive subjects</measure>
    <time_frame>Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited symptoms</measure>
    <time_frame>Within 4 days (Day 0 -Day 3) after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a grade &quot;3&quot; solicited symptoms</measure>
    <time_frame>Within 4 days (Day 0 -Day 3) after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events</measure>
    <time_frame>Within 31 days after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events</measure>
    <time_frame>Throughout the entire study up to (Month 0 to Month 9-10) and including 30 days after last vaccination (Month 9-10)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <condition>Diphtheria</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>DTPa 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DTPa 2 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)</intervention_name>
    <description>Three doses administered intramuscularly</description>
    <arm_group_label>DTPa 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)</intervention_name>
    <description>Three doses administered intramuscularly</description>
    <arm_group_label>DTPa 2 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male or female subject between 8 and 15 weeks of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject prior to
             the study entry.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Born after a normal gestation period between 36 and 42 weeks.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding the administration of the study vaccine, or planned
             use during the study period.

          -  Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis
             B and/or Hib vaccination or disease.

          -  Planned administration of a vaccine not foreseen by the study protocol since birth and
             during the period starting 30 days before the administration of the first dose and
             ending 30 days after the last dose of the three-dose primary vaccination course, with
             the exception of licensed Neisseria meningitides conjugate vaccines or Bacillus
             Calmette-Guérin (BCG) vaccine that can be given in between study visits or after the
             third visit, provided they are given preferably with a 4 weeks interval but not less
             than 3 weeks apart from the study vaccine doses.

          -  Chronic administration or planned administration of immuno-suppressants or other
             immune-modifying drugs since birth.

          -  Planned administration of immunoglobulins and/or any blood products since birth or
             planned administration during the period up to 30 days after the third dose of the
             primary vaccination course.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  History of seizures, progressive neurological disease or intra-cerebral haemorrhage.

          -  Major congenital defects or serious chronic illness.

          -  Acute febrile illness at the time of planned vaccination

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>15 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galatina (LE)</city>
        <state>Puglia</state>
        <zip>73013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maglie (LE)</city>
        <state>Puglia</state>
        <zip>73024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Kilpi et al. Comparison of the immunogenicity and reactogenicity of two hexavalent DTPa-HBV-IPV/Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Abstract presented at the 24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Basel Switzerland 03-05 May, 2006.</citation>
  </reference>
  <reference>
    <citation>Kilpi TM, Silfverdal SA, Nilsson L, Syrjänen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin. 2009 Jan-Feb;5(1):18-25. Epub 2009 Jan 2.</citation>
    <PMID>18690013</PMID>
  </reference>
  <reference>
    <citation>Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age. Vaccine. 2012 Apr 5;30(17):2710-4. doi: 10.1016/j.vaccine.2012.02.024. Epub 2012 Feb 18.</citation>
    <PMID>22349525</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HEXAVACTM</keyword>
  <keyword>InfanrixTM HEXA</keyword>
  <keyword>DTPa-HBV-IPV-Hib</keyword>
  <keyword>DTPa-HBV-IPV/Hib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>217744/094</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

